$279 Million is the total value of Endurant Capital Management LP's 49 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 138.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCM | Buy | R1 RCM INC | $21,244,000 | +103.3% | 2,378,963 | +186.3% | 7.62% | +85.0% |
| ZBH | Buy | ZIMMER BIOMET HLDGS INC | $20,933,000 | +62.2% | 152,496 | +39.1% | 7.51% | +47.6% |
| SPY | New | SPDR S&P 500 ETF TRput | $19,646,000 | – | 66,200 | +100.0% | 7.05% | – |
| HCA | Buy | HCA HEALTHCARE INC | $18,033,000 | +205.8% | 149,755 | +243.3% | 6.47% | +178.4% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $16,454,000 | +90.0% | 989,436 | +57.2% | 5.90% | +73.0% |
| LH | Buy | LABORATORY CORP AMER HLDGS | $14,949,000 | +4.3% | 88,983 | +7.3% | 5.36% | -5.1% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $14,804,000 | +278.2% | 291,925 | +238.3% | 5.31% | +244.3% |
| JNJ | New | JOHNSON & JOHNSON | $13,897,000 | – | 107,413 | +100.0% | 4.99% | – |
| PRAH | Buy | PRA HEALTH SCIENCES INC | $12,583,000 | +30.6% | 126,809 | +30.5% | 4.52% | +18.9% |
| ABBV | Buy | ABBVIE INC | $12,267,000 | +89.5% | 162,007 | +82.0% | 4.40% | +72.5% |
| CI | Buy | CIGNA CORP NEW | $10,945,000 | +12.8% | 72,109 | +17.1% | 3.93% | +2.7% |
| CRL | New | CHARLES RIV LABS INTL INC | $9,926,000 | – | 74,986 | +100.0% | 3.56% | – |
| ABC | Buy | AMERISOURCEBERGEN CORP | $8,686,000 | +38.6% | 105,501 | +43.5% | 3.12% | +26.1% |
| ZTS | New | ZOETIS INCcl a | $7,600,000 | – | 60,999 | +100.0% | 2.73% | – |
| ANTM | New | ANTHEM INC | $6,160,000 | – | 25,657 | +100.0% | 2.21% | – |
| BDX | New | BECTON DICKINSON & CO | $5,581,000 | – | 22,061 | +100.0% | 2.00% | – |
| IART | Buy | INTEGRA LIFESCIENCES HLDGS C | $5,059,000 | +111.5% | 84,225 | +96.7% | 1.82% | +92.6% |
| HAE | New | HAEMONETICS CORP | $4,111,000 | – | 32,594 | +100.0% | 1.48% | – |
| NCNA | New | NUCANA PLCsponsored adr | $2,785,000 | – | 384,700 | +100.0% | 1.00% | – |
| FATE | New | FATE THERAPEUTICS INC | $2,590,000 | – | 166,782 | +100.0% | 0.93% | – |
| BIO | Buy | BIO RAD LABS INCcl a | $2,299,000 | +96.8% | 6,910 | +85.0% | 0.82% | +79.3% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $1,911,000 | -46.4% | 1,769,785 | +8.6% | 0.69% | -51.2% |
| INSP | New | INSPIRE MED SYS INC | $1,880,000 | – | 30,805 | +100.0% | 0.68% | – |
| SDC | New | SMILEDIRECTCLUB INC | $1,851,000 | – | 133,388 | +100.0% | 0.66% | – |
| FLDM | New | FLUIDIGM CORP DEL | $1,832,000 | – | 395,701 | +100.0% | 0.66% | – |
| CNMD | New | CONMED CORP | $1,261,000 | – | 13,112 | +100.0% | 0.45% | – |
| PETQ | New | PETIQ INC | $936,000 | – | 34,354 | +100.0% | 0.34% | – |
| AXNX | New | AXONICS MODULATION TECH INC | $747,000 | – | 27,759 | +100.0% | 0.27% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $743,000 | – | 23,918 | +100.0% | 0.27% | – |
| PRTA | New | PROTHENA CORP PLC | $677,000 | – | 86,407 | +100.0% | 0.24% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $537,000 | – | 22,281 | +100.0% | 0.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-11-25
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.